Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Veracyte, Inc.

NASDAQ: VCYT · Industrial Applications and Services · 7 alerts · CIK 1384101

Share price
$24.01Close, Nov 16
Market cap
$1.94B
Shares outstanding
80.7MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Veracyte, Inc. filings on SEC EDGAR ↗

4:10 PM ET 8-K
Financial Results

Veracyte Financial Results

Veracyte reported Q3 2026 financial results with total revenue growing 15% year-over-year to $151.8 million, driven by strong performance in its Afirma and Decipher Prostate tests. The company also announced that its Board of Directors authorized a new $100 million share repurchase program to be executed over a one-year period.

“We delivered solid third quarter results supported by strong profitability and cash generation. Afirma outperformed, while Decipher Prostate volume was below our expectations. We remain confident in the long-term outlook of our business and expect a number of evidence-based catalysts to support growth in our core franchises while also advancing our breast and bladder strategies. As we execute on these opportunities, our differentiated financial profile enables us to continue investing in the business to drive long-term growth.”

Marc Stapley, chief executive officer of Veracyte

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.